nAlb-diABZI

nAlb-diABZI is a preclinical-stage therapeutic conjugate consisting of a Stimulator of Interferon Genes (STING) agonist, diABZI, covalently linked to a nanobody (VHH) that binds to serum albumin. Developed primarily by researchers at the University of Chicago, this molecule is designed to overcome the limitations of systemic STING activation, such as rapid clearance and off-target inflammatory toxicity. By binding to endogenous albumin, nAlb-diABZI achieves an extended circulatory half-life and exploits the neonatal Fc receptor (FcRn) recycling pathway. This allows for enhanced accumulation within tumors and tumor-draining lymph nodes, where it triggers the production of Type I interferons and activates innate immune cells, ultimately driving a potent CD8+ T-cell-mediated anti-tumor response. It is being investigated for the treatment of various solid tumors, often in combination with checkpoint inhibitors.

Other names

nanobody-diABZI conjugatealbumin-binding STING agonist conjugateVHH-diABZI